Nottingham, United Kingdom

University of Nottingham

www.nottingham.ac.uk
Nottingham, United Kingdom

The University of Nottingham is a public research university based in Nottingham, Nottinghamshire, England, United Kingdom. It was founded as University College Nottingham in 1881 and granted a Royal Charter in 1948.Nottingham's main campus, University Park, is situated on the outskirts of the City of Nottingham, with a number of smaller campuses and a teaching hospital located elsewhere in Nottinghamshire. Outside the United Kingdom, Nottingham has campuses in Semenyih, Malaysia and Ningbo, China. Nottingham is organised into five constituent faculties, within which there are more than 50 departments, institutes and research centres. Nottingham has around 44,000 students and 9,000 staff and had a total income of £520 million in 2012/13, of which £100 million was from research grants and contracts.Nottingham is currently ranked 23rd in the UK by the Complete University Guide Table 2015. Several of its subjects have been consistently ranked in the top ten, including Economics, Law, and Pharmacy. A 2014 survey suggested it is the most targeted university by the UK's top employers. In 2012 Nottingham was ranked 13th in the world in terms of the number of alumni listed among CEOs of the Fortune Global 500. It is also ranked 2nd in the 2012 Summer Olympics table of British medal winners. In the 2011 GreenMetric World University Ranking, Nottingham was the world's most sustainable campus.It is a member of the Association of Commonwealth Universities, the Virgo Consortium, the European University Association, the Russell Group, Universities UK, Universitas 21 and participates in the Sutton Trust Summer School programme. Wikipedia.


Time filter

Source Type

Patent
University of Nottingham | Date: 2016-12-27

A system (100) and method for determining the air leakage of a space (102) in a building is disclosed. The system (100) comprises a processor (120); a source (130) of compressed air; a pressure sensor (150) configured to measure the pressure of air residing within the space (130) and to provide background pressure signals to the processor (120); a nozzle unit (140) for metering the supply of a pulse of compressed air from the source (130) and for directing the pulse into the space (102) and a source pressure sensor (132) configured to measure a transient pressure during the pulse and to provide a transient pressure signal to the processor (120), wherein the processor (120) is configured to determine the air leakage based on changes in the background pressure signals and from the transient pressure signal. This provides a more reliable and cost effective way of measuring air leakage.


Patent
University of Nottingham | Date: 2017-05-03

A system (100) and method for determining the air leakage of a space (102) in a building is disclosed. The system (100) comprises a processor (120); a source (130) of compressed air; a pressure sensor (150) configured to measure the pressure of air residing within the space (130) and to provide background pressure signals to the processor (120); a nozzle unit (140) for metering the supply of a pulse of compressed air from the source (130) and for directing the pulse into the space (102); and a source pressure sensor (132) configured to measure a transient pressure during the pulse and to provide a transient pressure signal to the processor (120), wherein the processor (120) is configured to determine the air leakage based on changes in the background pressure signals and from the transient pressure signal. This provides a more reliable and cost effective way of measuring air leakage.


Patent
University of Nottingham | Date: 2017-02-01

Apparatus for the assessment of visual function and ocular motility and the treatment of disorders thereof, comprising ocular display apparatus which presents different, but visually related, images to each eye. The invention also relates to methods of assessment of ocular disorders and to their treatment.


Patent
Ecoles Des Hautes En Sante Publique Ehesp, University of the French West Indies, Guiana and University of Nottingham | Date: 2017-02-22

The present invention relates to polypeptides and uses thereof for reducing CD95-meditated cell motility. In particular, the present invention relates to a polypeptide having an amino acid sequence having at least 70% of identity with the amino acid sequence ranging from the amino-acid residue at position 175 to the amino-acid residue at position 191 in SEQ ID NO:1.


Patent
Nottingham Trent University and University of Nottingham | Date: 2017-01-27

There has been a recent shift in cancer therapy from one size fits all to a personalized and tailored treatment for individual patients to increase efficiency and avoid unnecessary toxicity. This invention relates to a method of determining the prognosis and suitable treatment of cancer in a subject by measuring the level of expression of SPAG5. In particular, it relates to a method where high expression of SPAG5 in tumour cells correlates with aggressive tumors.


Patent
University of Nottingham | Date: 2017-02-15

A capillary refill measurement apparatus (1), comprising a support element (14) configured to receive the weight of a user through their foot, a light source (22) for illuminating a region of the foot that exerts weight onto the support element (14), a light detector (24) arranged to receive light from the illuminated region (36) of the foot and generate an output based on the received light, and a processor (26) configured to determine a capillary refill rate from the output of the light detector (24) when the user adjusts the amount of weight received by the support element (14).


The invention relates to a method for producing functionalised monomers, the method comprising: a) providing a starting material selected from terpenes and terpenoids; b) forming a derivative of the starting material by incorporation of a hydroxyl group; c) esterifying the hydroxyl group of the derivative to introduce a moiety containing a vinyl group, so as to produce a functionalised monomer. The functionalised monomer can be polymerised to obtain a bio-derived polymer.


Patent
University of Nottingham | Date: 2017-06-28

A method of manufacture of a powder comprising, or consisting essentially of, microspheres, the method comprising: providing a feed powder; and applying at least one spheroidisation flame to the powder. The powder may be suitable for use in medical and/or non-medical applications.


Patent
University of Nottingham | Date: 2017-07-19

The invention relates to a modified spidroin, comprising spidroin modified to comprise azide, alkyne, allyl or amine moieties; a spider silk material; a conjugate of spidroin and an active molecule linked by a triazole or amide; a tissue scaffold, implant, wound dressing, or suture, comprising the modified spidroin; methods of forming and modifying spidroin; and methods of treatment comprising the administration of the modified spidroin.


Background High blood pressure is associated with poor outcome after stroke. Whether blood pressure should be lowered early after stroke, and whether to continue or temporarily withdraw existing antihypertensive drugs, is not known. We assessed outcomes after stroke in patients given drugs to lower their blood pressure. Methods In our multicentre, partial-factorial trial, we randomly assigned patients admitted to hospital with an acute ischaemic or haemorrhagic stroke and raised systolic blood pressure (systolic 140-220 mm Hg) to 7 days of transdermal glyceryl trinitrate (5 mg per day), started within 48 h of stroke onset, or to no glyceryl trinitrate (control group). A subset of patients who were taking antihypertensive drugs before their stroke were also randomly assigned to continue or stop taking these drugs. The primary outcome was function, assessed with the modified Rankin Scale at 90 days by observers masked to treatment assignment. This study is registered, number ISRCTN99414122. Findings Between July 20, 2001, and Oct 14, 2013, we enrolled 4011 patients. Mean blood pressure was 167 (SD 19) mm Hg/90 (13) mm Hg at baseline (median 26 h [16-37] after stroke onset), and was significantly reduced on day 1 in 2000 patients allocated to glyceryl trinitrate compared with 2011 controls (difference -7·0 [95% CI -8·5 to -5·6] mm Hg/-3·5 [-4·4 to -2·6] mm Hg; both p<0·0001), and on day 7 in 1053 patients allocated to continue antihypertensive drugs compared with 1044 patients randomised to stop them (difference -9·5 [95% CI -11·8 to -7·2] mm Hg/-5·0 [-6·4 to -3·7] mm Hg; both p<0·0001). Functional outcome at day 90 did not differ in either treatment comparison - the adjusted common odds ratio (OR) for worse outcome with glyceryl trinitrate versus no glyceryl trinitrate was 1·01 (95% CI 0·91-1·13; p=0·83), and with continue versus stop antihypertensive drugs OR was 1·05 (0·90-1·22; p=0·55). Interpretation In patients with acute stroke and high blood pressure, transdermal glyceryl trinitrate lowered blood pressure and had acceptable safety but did not improve functional outcome. We show no evidence to support continuing prestroke antihypertensive drugs in patients in the first few days after acute stroke. Funding UK Medical Research Council. © 2015 Bath et al. Open Access article distributed under the terms of CC BY.

Loading University of Nottingham collaborators
Loading University of Nottingham collaborators